● TIER 3 — Information onlyGRADE BImmune / thymic
LL-37
Cathelicidin. Research verification: Yes (TGA pending). 1 human study record(s) in the FitClinicMD studies database.
GOALS · Recovery / injury
FDA status
Not approved.
Compounding (503A/503B)
Listed by FDA under 'nominated but withdrawn' from Category 2 (i.e., no longer in Category 2, but NOT on the 503A bulks list or Category 1) — (nonclinical male-reproduction and protumorigenic signals).
DEA
Not controlled.
WADA (sport)
Not listed on 2026 Prohibited List (no matching section found)
Mechanism
Antimicrobial/immunomodulatory.
Human evidence · 1
Phase 1/2 topical venous leg ulcers, n=34. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial.
Reference only. This page summarizes publicly available regulatory and research information about LL-37. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.